Increased serum CRH levels with decreased skin CRHR-1 gene expression in psoriasis and atopic dermatitis

Vasiadi, Magdalini; Therianou, Anastasia; Sideri, Kyriaki; Smyrnioti, Marilena; Sismanopoulos, Nikolaos; Delivanis, Danae A.; Asadi, Shahrzad; Katsarou-Katsari, Alexandra; Petrakopoulou, Theodora; Theoharides, Athanasios; Antoniou, Christina; Papadavid, E.; Stavrianeas, Nikolaos; Kalogeromitros, D.; Tc, Theoharides

doi:10.1016/j.jaci.2012.01.041

Cited by 56 publications

(46 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, there is evidence of cross-talk between microglia and MCs (Skaper et al, 2014). It is interesting that the diseases discussed above worsen with stress (Theoharides and Cochrane, 2004;Vasiadi et al, 2012;Theoharides et al, 2012b;Karagkouni et al, 2013), and MCs are activated by corticotropin-releasing hormone secreted under stress Cao et al, 2005).…”

Section: Functional and Pathologic Features Of Il-33 In Allergic Disementioning

confidence: 99%

Targeting IL-33 in Autoimmunity and Inflammation

Theoharides

Petra

Taracanova

et al. 2015

J Pharmacol Exp Ther

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Functional and Pathologic Features Of Il-33 In Allergic Disementioning

confidence: 99%

Targeting IL-33 in Autoimmunity and Inflammation

Theoharides

Petra

Taracanova

et al. 2015

J Pharmacol Exp Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…107,108 Corticotropin-releasing hormone, which downregulates IL-10 production by adaptive forkhead box protein 3-negative regulatory T cells, 109 has been recently found to have altered expression in patients with AD. 110 Although AD is known as a T H 2-and T H 22-mediated inflammatory skin disease, and psoriasis is known as a T H 1/T H 17-mediated skin disease, 111 there might be AD subsets that do not follow this rule. Indeed, IL-17 expression has been reported in mouse models of eczema.…”

Section: Immunologic Responsesmentioning

confidence: 99%

Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2012

Sicherer

Leung

2013

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

This review highlights some of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects; and allergic skin diseases that were reported in the Journal in 2012. Studies support an increase in peanut allergy prevalence in children and exposure to the antibacterial agent triclosan and having filaggrin (FLG) loss-of-function mutations as risk factors for food sensitization. The role of specific foods in causing eosinophilic esophagitis is elucidated by several studies, and microRNA analysis is identified as a possible noninvasive disease biomarker. Studies on food allergy diagnosis emphasize the utility of component testing and the possibility of improved diagnosis through stepped approaches, epitope-binding analysis, and bioinformatics. Treatment studies of food allergy show promise for oral immunotherapy, but tolerance induction remains elusive, and additional therapies are under study. Studies on anaphylaxis suggest an important role for platelet-activating factor and its relationship to the need for prompt treatment with epinephrine. Insights on the pathophysiology and diagnosis of non-IgE-mediated drug allergy are offered, with novel data regarding the interaction of drugs with HLA molecules. Numerous studies support influenza vaccination of persons with egg allergy using modest precautions. Evidence continues to mount that there is cross-talk between skin barrier defects and immune responses in patients with atopic dermatitis. Augmentation of the skin barrier with reduction in skin inflammatory responses will likely lead to the most effective intervention in patients with this common skin disease.

show abstract

“…11;12 MC-derived CCL2 13 and CXCL-8 ( IL-8) enhance recruitment of immune cells to the site of inflammation. 6;7;14 The ability to release multiple mediators allows MC to actively interact with other cell types in their surrounding environment, and participate in the induction and/or propagation of various immune and inflammatory responses including mastocytosis, 15 asthma 16 , atopic dermatitis, 17 and psoriasis. 3;16;18;19 Therefore, inhibition of MC activation has clear therapeutic potential.…”

Section: Introductionmentioning

confidence: 99%

The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells

Weng

Patel

Panagiotidou

et al. 2015

Journal of Allergy and Clinical Immunology

Self Cite

121

114

View full text Add to dashboard Cite

Background Mast cells (MCs) are hemopoietic cells that mature in tissues and are involved in allergy, immunity and inflammation by secreting multiple mediators. The natural flavone luteolin (lut) has anti-inflammatory actions and inhibits human MCs. Objective To investigate the ability of lut, and its novel structural analog 3’,4’,5,7-tetramethoxyluteolin (methlut), to inhibit human MCs mediator expression and release in vitro and in vivo. Methods Human LAD2 cells and primary human umbilical cord-blood derived cultured MC (hCBMCs) were stimulated by substance P (SP) or IgE/anti-IgE with or without pre-incubation with lut, methlut or cromolyn (1–100 μM) for 2 or 24 hr following which a mediator secretion was measured. The effect of the compound on MC intracellular calcium levels and NF-κB activation was also investigated. Pretreatment with methlut was also studied in mice passively sensitized with dinotrophenol-human serum albumin (DNP-HSA) and challenged intradermally. Results Methlut is a more potent inhibitor than lut or cromolyn for beta-hexosaminidase (β-hex) and histamine secretion from LAD2 cells stimulated by either SP or IgE/anti-IgE, but only methlut and lut significantly inhibit preformed tumor necrosis factor (TNF) secretion. Methlut is also a more potent inhibitor than lut of de novo synthesized TNF from LAD2, and of chemokine (C-C motif) ligand 2 (CCL2) from hCBMCs. The mechanism of action from methlut may be due to its ability to inhibit intracellular calcium increase, as well as NF-κB induction at both the transcriptional and translational levels in LAD2 cells stimulated by SP without affecting cell viability. Treatment (ip) with methlut significantly decreases skin vascular permeability of Evans blue in mice passively sensitized to DNP-HAS and challenged intradermaly. Conclusion Methlut is a promising MC inhibitor for the treatment of allergic and inflammatory conditions.

show abstract

Increased serum CRH levels with decreased skin CRHR-1 gene expression in psoriasis and atopic dermatitis

Abstract: There is increased serum CRH with decreased lesional skin CRHR-1 gene expression in psoriasis and atopic dermatitis, suggesting possible involvement in stress-induced worsening of symptoms.

Cited by 56 publications

References 10 publications

Targeting IL-33 in Autoimmunity and Inflammation

Targeting IL-33 in Autoimmunity and Inflammation

Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2012

The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells

Contact Info

Product

Resources

About